Precision Biosciences Inc (NASDAQ: DTIL) has experienced a decline in its stock price by -10.56 compared to its previous closing price of 4.26. However, the company has seen a fall of -15.33% in its stock price over the last five trading days. businesswire.com reported 2024-12-18 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it has received Clinical Trial Application (CTA) approval in Hong Kong to study PBGENE-HBV in the ongoing ELIMINATE-B Phase I trial. PBGENE-HBV is Precision’s lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by.
Is It Worth Investing in Precision Biosciences Inc (NASDAQ: DTIL) Right Now?
The price-to-earnings ratio for Precision Biosciences Inc (NASDAQ: DTIL) is above average at 74.56x, Company’s 36-month beta value is 1.49.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DTIL is 3.73M, and currently, short sellers hold a 7.36% ratio of that floaft. The average trading volume of DTIL on January 01, 2025 was 107.62K shares.
DTIL’s Market Performance
DTIL’s stock has seen a -15.33% decrease for the week, with a -47.74% drop in the past month and a -58.13% fall in the past quarter. The volatility ratio for the week is 11.17%, and the volatility levels for the past 30 days are at 9.84% for Precision Biosciences Inc The simple moving average for the past 20 days is -25.58% for DTIL’s stock, with a -60.64% simple moving average for the past 200 days.
Analysts’ Opinion of DTIL
Many brokerage firms have already submitted their reports for DTIL stocks, with Guggenheim repeating the rating for DTIL by listing it as a “Buy.” The predicted price for DTIL in the upcoming period, according to Guggenheim is $19 based on the research report published on April 30, 2024 of the previous year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see DTIL reach a price target of $7. The rating they have provided for DTIL stocks is “Outperform” according to the report published on June 17th, 2022.
DTIL Trading at -44.02% from the 50-Day Moving Average
After a stumble in the market that brought DTIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.39% of loss for the given period.
Volatility was left at 9.84%, however, over the last 30 days, the volatility rate increased by 11.17%, as shares sank -44.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.38% lower at present.
During the last 5 trading sessions, DTIL fell by -15.33%, which changed the moving average for the period of 200-days by -66.19% in comparison to the 20-day moving average, which settled at $5.12. In addition, Precision Biosciences Inc saw -65.21% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DTIL starting from Buehler Kevin, who purchase 4,320 shares at the price of $4.88 back on Dec 27 ’24. After this action, Buehler Kevin now owns 8,712 shares of Precision Biosciences Inc, valued at $21,082 using the latest closing price.
Kelly John Alexander, the Chief Financial Officer of Precision Biosciences Inc, purchase 2,113 shares at $4.75 during a trade that took place back on Dec 27 ’24, which means that Kelly John Alexander is holding 40,186 shares at $10,037 based on the most recent closing price.
Stock Fundamentals for DTIL
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.93 for the gross margin
The net margin for Precision Biosciences Inc stands at 0.11. The total capital return value is set at -0.11. Equity return is now at value 24.44, with 7.23 for asset returns.
Based on Precision Biosciences Inc (DTIL), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -2.05. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is -8.23.
Currently, EBITDA for the company is -32.04 million with net debt to EBITDA at -3.64. When we switch over and look at the enterprise to sales, we see a ratio of -0.52. The receivables turnover for the company is 48.54for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.22.
Conclusion
In a nutshell, Precision Biosciences Inc (DTIL) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
